

Accelerated Publications

Molecular Cloning of Three Distinct Forms of the Na^+, K^+ -ATPase α -Subunit from Rat Brain[†]

Gary E. Shull, Jeannette Greeb, and Jerry B. Lingrel*

Department of Microbiology and Molecular Genetics, University of Cincinnati College of Medicine,
Cincinnati, Ohio 45267-0524

Received September 3, 1986; Revised Manuscript Received October 9, 1986

ABSTRACT: Rat brain and kidney cDNA libraries were constructed and screened with a cDNA insert corresponding to the mRNA for the sheep kidney Na^+, K^+ -ATPase catalytic subunit. The α -subunit cDNAs isolated from the kidney library were derived from a single class of messenger RNA, and the brain cDNAs were derived from three classes of messenger RNA. The most abundant brain cDNA, which spans 5.1 kilobases, encodes the $\alpha(+)$ form of the enzyme. The second most abundant brain cDNA, which spans 3.65 kilobases, is identical with that of the kidney form and therefore encodes the α isoform. The third class of cDNA, which spans 3.55 kilobases, was present at low abundance and encodes an isoform of the α -subunit, designated αIII , which has not been identified previously. The complete nucleotide sequence and deduced amino acid sequence for each of the brain and kidney cDNAs have been determined. In addition, we have identified a lysine-rich sequence that may function as a movable, ion-selective gate during cation binding and occlusion and have also identified several amino acid sequence variations that appear to explain some of the well-known species and tissue differences in cardiac glycoside sensitivity.

The Na^+, K^+ -ATPase is an integral membrane protein that catalyzes the active transport of Na^+ and K^+ across the plasma membrane of animal cells [for reviews see Stahl (1986) and Schwartz et al. (1975)]. The enzyme consists of two subunits, a catalytic subunit (α) of M_r 112 000 and a glycoprotein subunit (β) of unknown function with an M_r of 35 000 for the protein component. The complete amino acid sequences for the α and β subunits from sheep kidney (Shull et al., 1985, 1986), pig kidney (Ovchinnikov et al., 1986), and *Torpedo californica* electric organ (Kawakami et al., 1985; Noguchi et al., 1986) have been determined from their cDNAs. However, in mammals there are at least two isoforms of the catalytic subunit. Besides the well-characterized renal form, which is designated α , there is an additional form, termed $\alpha(+)$, which has been identified in several tissues. For example, brain tissue contains a form that appears to be identical with the renal form (α) as well as the $\alpha(+)$ form, which has a higher apparent molecular weight on SDS¹-polyacrylamide

gels (Sweadner, 1979). The two forms also differ in cardiac glycoside sensitivity (Sweadner, 1979), N-terminal amino acid sequence (Lytton, 1985a), and Na^+ affinity (Lytton, 1985b). There is evidence that the $\alpha(+)$ form in adipocytes, which may be identical with the brain $\alpha(+)$, is responsive to insulin whereas the α form is not (Lytton, 1985b; Lytton et al., 1985).

The present study was conducted in order to determine the complete primary structure of the rat α and $\alpha(+)$ forms of the catalytic subunit and to identify amino acid sequence differences between these isoforms, which might provide information regarding functional differences such as cardiac glycoside sensitivity. Therefore, we prepared and screened cDNA libraries from rat kidney, which contains the ouabain-resistant α form, and rat brain in which the predominant form is the ouabain-sensitive $\alpha(+)$ isoform. As the full sequences of the ouabain-sensitive sheep and pig kidney enzymes

[†] This work was supported by NIH Research Grant HL28573 and NSF Instrument Grant DMB8414251.

* Correspondence should be addressed to this author.

¹ Abbreviations: SDS, sodium dodecyl sulfate; cDNA, complementary deoxyribonucleic acid; mRNA, messenger ribonucleic acid; SET, 0.15 M NaCl, 20 mM Tris-HCl, pH 7.8, and 1 mM ethylenediaminetetraacetic acid; Denhardt's solution, 0.02% (w/v) bovine serum albumin, 0.02% (w/v) poly(vinylpyrrolidone), and 0.02% (w/v) Ficoll; nt(s), nucleotide(s); Tris, tris(hydroxymethyl)aminomethane; kb, kilobase(s).




FIGURE 1: Restriction map and sequencing strategy for the Na^+, K^+ -ATPase α -subunit isoforms of rat kidney and brain. Open areas represent the open reading frame and darkened areas represent untranslated regions. Restriction sites relevant to the sequencing strategy are shown. The direction and extent of sequencing are shown by arrows (lower arrows, coding strand; upper arrows, noncoding strand). The brain (clone B1-4) and kidney (clone K3-2) α -form cDNAs were virtually identical (see Figure 2 legend), and therefore the kidney cDNA sequence (K) was determined in only one strand. The sequence of $\alpha(+)$ was determined from clone B4-4, which ended at a polyadenylation signal indicated by the vertical arrow; the remaining $\alpha(+)$ sequence was determined from clone B9-5, which ended at a different polyadenylation site. The sequence of brain αIII was determined from clone B3-5.

are known from their cDNAs, the isolation of these rat cDNAs also allows an investigation of species differences in cardiac glycoside sensitivity.

EXPERIMENTAL PROCEDURES

Preparation of Brain and Kidney cDNA Libraries. Poly-(A⁺) RNA was isolated from male rat (CD strain, Charles River Breeding Laboratory) brain and kidney as described previously (Snider et al., 1985). First- and second-strand cDNA syntheses, size fractionation of double-stranded cDNA, tailing of the 3.3–5.5-kb fraction with deoxycytidine 5'-triphosphate, annealing of cDNA to G-tailed *Pst*I-cut pBR322, plating of the libraries, and preparation of replica filters were performed as described previously (Shull et al., 1985). Each library consisted of 50 000 colonies on ten 150-mm plates.

Screening of cDNA Library. The 20 replica filters of each library were prehybridized overnight at 68 °C in 6 × SET, 5 × Denhardt's solution, 0.1% SDS, and 100 µg of denatured salmon sperm DNA/mL and then hybridized with a ³²P-labeled (Maniatis et al., 1982) 2.7-kb *Xho*I–*Bgl*II fragment from a sheep kidney Na^+, K^+ -ATPase α -subunit cDNA (Shull et al., 1985). Hybridization was performed at 58 °C for 24 h in 60 mL of the same solution containing 5×10^6 dpm/mL. The filters were washed 4 times for 30 min each at 58 °C in 6 × SET and 0.1% SDS and then washed for 1 h at 58 °C in 3 × SET and 0.1% SDS. Following autoradiography the filters were washed for 1 h at 63 °C in 1.5 × SET and 0.1% SDS and then subjected to autoradiography a second time. Colonies that gave signals on both replicas were isolated, and plasmid DNA was extracted by the alkaline lysis procedure (Maniatis et al., 1982).

Characterization of cDNAs. Brain and kidney cDNAs were analyzed by restriction mapping according to standard protocols (Maniatis et al., 1982). DNA sequence analysis was performed by the method of Maxam and Gilbert (1980). The nucleotide sequence was determined at least once in both strands for each of the brain isoforms except for nts 1–47 and 4866–5107 of $\alpha(+)$, which were determined from only one strand. The kidney α form cDNA sequence was analyzed in only one strand because it was virtually identical with the brain α form (see Figure 2 legend).

RESULTS

Isolation of Brain and Kidney α -Subunit cDNAs. Screening of rat brain and kidney cDNA libraries with a sheep kidney Na^+, K^+ -ATPase α -subunit hybridization probe resulted in 78 positive signals in the brain library and 117 positive signals in the kidney library. Eight kidney and 25 brain cDNAs were colony purified and analyzed by restriction mapping. The kidney cDNAs exhibited a single restriction pattern whereas the brain cDNAs had three distinct patterns (diagrammed in Figure 1). The medium-abundance (six isolates) brain class had a 3.65-kb insert, and its restriction pattern was identical with that of the kidney form. The relative abundance of this class and its similarity to the kidney class (Sweadner, 1979; Schmitt & McDonough, 1986) suggested that it was derived from the α -form mRNA. The most abundant class of brain cDNA (16 isolates) was 5.1 kb in length and had a very different restriction pattern from the kidney form. Its relative abundance indicated that it was derived from the $\alpha(+)$ mRNA. The third class of cDNA (three isolates) had a 3.55-kb insert. This class of cDNA is apparently derived from

FIGURE 2: Nucleotide sequence of the cDNA for the Na⁺,K⁺-ATPase α isoform of rat kidney and brain. The sequence shown is for brain cDNA B1-4. Kidney cDNA K3-2 was identical except that it was missing the first three nts of the sequence and had Cs, rather than Ts, at positions 97 and 1680. The deduced amino acid sequence is numbered starting with the N-terminus of the mature protein (Lytton, 1985a) and is preceded by five amino acids occurring in the primary translation product. The phosphorylation site (Asp-371) is indicated by P and the major hydrophobic domains (H1-H8) are underlined.

The brain and kidney α -form cDNAs are identical except for several nt differences (see Figure 2 legend), which did not result in amino acid substitutions. They have a 237-nt 5'-untranslated sequence, a 1023 codon open reading frame, and 328 nts of 3'-untranslated sequence. The initiation codon is the first ATG triplet encountered in the sequence and lies in a perfect 9-nt consensus sequence for initiation of translation (Kozak, 1984). Residues 1-14 of the deduced amino acid sequence are identical with those of the N-terminal sequence of the rat brain α form determined previously (Lytton, 1985a); five amino acids, which are apparently removed by post-

The identity of the $\alpha(+)$ form (Figure 3) was confirmed by comparison of the deduced N-terminal amino acid sequence (GREYSPAATTAENG) with that determined by analysis of the rat brain $\alpha(+)$ protein (GREYSPAEEVAEVG) (Lytton, 1985a). Although mismatches occurred at residues 9, 10, and 13, it seems possible that this was due to errors in the original amino acid sequence analysis; in the study cited the problem of a rapidly rising background during each cycle of amino acid analysis was noted. In addition, a hybridization probe consisting of mixed oligonucleotides derived from the sequence AEVAEV, which contained the residues in question, failed to hybridize with any of the 25 brain cDNAs (data not shown). The $\alpha(+)$ cDNA contains a 96-nt 5'-untranslated region, a 1020 codon open reading frame that begins with the first ATG triplet, and 1851 nts of 3'-untranslated sequence. There are three potential poliovirus signals (beginning

Organization of the α -Subunit Isoforms. The general organization of all three isoforms appears to be identical with that of the sheep (Shull et al., 1985), pig (Ovchinnikov et al., 1986), and *T. californica* enzymes (Kawakami et al., 1985) described previously. Four major hydrophobic domains (H1-H4), determined by hydropathy analysis (Kyte & Doolittle, 1982), occur in the N-terminal third of the protein, and each domain appears to represent a single transmembrane pass. The phosphorylation site (Bastide et al., 1973) occurs

FIGURE 4: Nucleotide sequence of the cDNA (B3-5) for the Na⁺,K⁺-ATPase α III isoform of rat brain. The deduced amino acid sequence is numbered by starting with the initiating methionine. The phosphorylation site (Asp-366) is indicated by P and the major hydrophobic domains (H1-H8) are underlined.

Amino Acid and Nucleotide Sequence Similarities. Pair-wise amino acid homology comparisons between the different isoforms gave the following values for percent identity: α vs. $\alpha(+)$, 86.3%; α vs. α III, 85.3%; $\alpha(+)$ vs. α III, 86.3%. A comparison of the three rat isoforms with the α -subunit of *T. californica* electric organ (Kawakami et al., 1985) gave the following values: α , 86.6%; $\alpha(+)$, 83.3%; α III, 83.0%. The

Presence of a Lysine-Rich Sequence in the N-Terminal Region. A comparison of the N-terminal sequences of the three rat α -subunit isoforms and the α -subunits of sheep (Shull et al., 1985) and pig (Ovchinnikov et al., 1986) kidney, *T. californica* electric organ (Kawakami et al., 1985), and the

amino acids adjacent to the transmembrane domains.

DISCUSSION

The existence of multiple forms of the Na^+, K^+ -ATPase has been known for many years, but questions have remained concerning the number of isoforms, their genetic basis, and their functional and structural differences. In order to address these questions, we isolated and characterized Na^+, K^+ -ATPase α -subunit cDNAs from rat kidney and brain. In addition to cDNAs for the well-known α and $\alpha(+)$ forms we isolated cDNAs for a third brain form, designated αIII , that had not been identified previously. The αIII mRNA is clearly not the product of a pseudogene as the sequence shows that it has the translation start and stop signals and open reading frame of over 1000 codons expected for a functional α -subunit mRNA. The existence of αIII , which was not predicted by the available biochemical data, raises the possibility that there may be additional isoforms besides the three presented here. A definitive answer regarding the genetic basis for the multiple α -subunit isoforms will require the isolation and characterization of their genomic sequences. However, on the basis of the data presented here it seems clear that they are the products of separate genes. If they were the result of differential processing of a single gene, then there should be some coding regions in common. This is not the case. Although amino acid sequence comparisons reveal extensive regions of perfect identity, the codon usage within these regions differs. The nucleotide homology in the protein coding region is less than 80%, and there is little detectable homology in the untranslated regions. As the amino acid homology between the three rat isoforms is about the same as that with the *Torpedo* enzyme, it seems likely that divergence of the genes encoding the three isoforms was an ancient evolutionary event.

It is known that Na^+ and K^+ are occluded within the Na^+, K^+ -ATPase during each turnover of the pump and that occlusion requires conformational changes in the enzyme (Beaugé & Glynn, 1979; Glynn et al., 1984). One of the lysine residues that lies within the lysine-rich sequence appears to correspond to trypsin site 2 (see Figure 5), which is highly accessible in the E_1Na conformation but much less accessible in the E_2K form [for a review see Jørgensen et al. (1982a,b)]. Proteolytic cleavage at this site alters the equilibrium between the E_1 and E_2 conformations (Jørgensen & Karlsh, 1980). Thus, it appears that the conformational shift that results in cation occlusion involves movement of the lysine-rich sequence. A possible function of this domain is to serve as a movable, ion-selective gate, which controls the passage of Na^+ and K^+ to and from the binding sites occupied during certain stages of the transport process. Positively charged amino acid side chains would be a logical feature of a gate controlling passage of cations.

Species and isoform differences in cardiac glycoside sensitivity are known to be due to large differences in the dissociation rate rather than in the association rate (Tobin & Brody, 1972). For the sensitive enzymes, but not for the resistant forms, binding of the drug is apparently followed by a conformational change that results in a stable, enzymatically inactive complex. Akera et al. (1979a) proposed that the resistant species lack a "lipid barrier" that regulates the release of cardiac glycosides. This hypothesis was based on the observation that, for the sensitive enzymes, K^+ lowers the rate of release of the more hydrophilic drugs but has little effect on the rate of release of the more hydrophobic compounds (Akera & Brody, 1971; Akera et al., 1974, 1978, 1979b). This proposal is consistent with the observed amino acid differences between rat α and the sensitive forms (Figure 6). It is possible

that conformational changes occurring after ouabain binding to the sensitive forms involve alterations in the relationship of the H1-H2 junction with the lipid bilayer and that these alterations allow the formation of a stable complex. In the case of rat α the presence of the charged amino acids Arg and Asp at the boundaries of the H1-H2 junction might interfere with such an alteration. Hence, the lipid barrier that prevents dissociation from a sensitive enzyme does not form in the resistant enzyme. It is possible that one or more of the other changes in rat α , such as the Pro in the H1-H2 junction, are compensatory changes that allow the necessary range of conformations that must occur during the catalytic cycle.

Previous studies using photoaffinity and other types of derivatives of ouabain (Fortes, 1977; Goeldner et al., 1983; Jørgensen et al., 1982a) and examination of the amino acid sequence derived from a cDNA (Shull et al., 1985) indicate that the ouabain binding site may be composed of several regions distantly separated in the primary sequence. From these previous studies it appears that ouabain binds to sequences in the C-terminal regions and to the H3-H4 junction. The results of the present study suggest that the H1-H2 junction is also involved. It could conceivably interact with the lactone ring. Thomas et al. (1974) have suggested that the lactone ring may fit into a cleft on the surface of the enzyme that contains one or more anionic sites. With the availability of cDNAs containing the entire coding regions of the sensitive and insensitive forms of the enzyme, it is now possible to test these and other hypotheses concerning the molecular basis of cardiac glycoside binding and sensitivity by using site-directed mutagenesis techniques.

ACKNOWLEDGMENTS

We thank Greg Wernke for help with the computer analysis, Earl Wallick, Lois Lane, and Marcia Shull for reading the manuscript, and Rose McCormick and Becky Howland for preparing the manuscript.

REFERENCES

- Ahmed, K., Rohrer, D. C., Fullerton, D. S., Deffo, T., Katsutani, E., & From, A. H. L. (1983) *J. Biol. Chem.* 258, 8092-8097.
- Akera, T., & Brody, T. M. (1971) *J. Pharmacol. Exp. Ther.* 176, 545-557.
- Akera, T., Tobin, T., Gatti, A., Shieh, I.-S., & Brody, T. M. (1974) *Mol. Pharmacol.* 10, 509-518.
- Akera, T., Temma, K., Wiest, S. A., & Brody, T. M. (1978) *Naunyn-Schmiedeberg's Arch. Pharmacol.* 304, 157-165.
- Akera, T., Yamamoto, S., Chubb, J., McNish, R., & Brody, T. M. (1979a) *Naunyn-Schmiedeberg's Arch. Pharmacol.* 308, 81-88.
- Akera, T., Wiest, S. A., & Brody, T. M. (1979b) *Eur. J. Pharmacol.* 57, 343-351.
- Bastide, F., Meissner, G., Fleischer, S., & Post, R. L. (1973) *J. Biol. Chem.* 248, 8385-8391.
- Beaugé, L. A., & Glynn, I. M. (1979) *Nature (London)* 280, 510-512.
- de Jong, W. W., Zweers, A., & Cohen, L. H. (1978) *Biochem. Biophys. Res. Commun.* 82, 532-539.
- Farley, R. A., Tran, C. M., Carilli, C. T., Hawke, D., & Shively, J. E. (1984) *J. Biol. Chem.* 259, 9532-9535.
- Fortes, P. A. G. (1977) *Biochemistry* 16, 531-540.
- Glynn, I. M., Hara, Y., & Richards, D. E. (1984) *J. Physiol. (London)* 351, 531-547.
- Goeldner, M. P., Hirth, C. G., Rossi, B., Ponzio, G., & Lazdunski, M. (1983) *Biochemistry* 22, 4685-4690.

- Jørgensen, P. L., & Karlsh, S. J. D. (1980) *Biochim. Biophys. Acta* 597, 305-317.
- Jørgensen, P. L., Karlsh, S. J. D., & Gitler, C. (1982a) *J. Biol. Chem.* 257, 7435-7442.
- Jørgensen, P. L., Skriver, E., Hebert, H., & Maunsbach, A. B. (1982b) *Ann. N.Y. Acad. Sci.* 402, 207-225.
- Kawakami, K., Noguchi, S., Noda, M., Takahashi, H., Ohta, T., Kawamura, M., Nojima, H., Nagano, K., Hirose, T., Inayama, S., Hayashida, H., Miyata, T., & Numa, S. (1985) *Nature (London)* 316, 733-736.
- Kirley, T. L., Wallick, E. T., & Lane, L. K. (1984) *Biochem. Biophys. Res. Commun.* 125, 767-773.
- Kozak, M. (1984) *Nucleic Acids Res.* 12, 857-872.
- Krebs, E. G., & Beavo, J. A. (1979) *Annu. Rev. Biochem.* 48, 923-959.
- Kyte, J., & Doolittle, R. F. (1982) *J. Mol. Biol.* 157, 105-132.
- Lingham, R. B., & Sen, A. K. (1982) *Biochim. Biophys. Acta* 688, 475-485.
- Lytton, J. (1985a) *Biochem. Biophys. Res. Commun.* 132, 764-769.
- Lytton, J. (1985b) *J. Biol. Chem.* 260, 10075-10080.
- Lytton, J., Lin, J. C., & Guidotti, G. (1985) *J. Biol. Chem.* 260, 1177-1184.
- MacLennan, D. H., Brandl, C. J., Korczak, B., & Green, N. M. (1985) *Nature (London)* 316, 696-700.
- Maniatis, T., Fritsch, E. F., & Sambrook, J. (1982) in *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
- Maxam, A. M., & Gilbert, W. (1980) *Methods Enzymol.* 65, 499-560.
- Morohashi, M., & Kawamura, M. (1984) *J. Biol. Chem.* 259, 14928-14934.
- Noguchi, S., Noda, M., Takahashi, H., Kawakami, K., Ohta, T., Nagano, K., Hirose, T., Inayama, S., Kawamura, M., & Numa, S. (1986) *FEBS Lett.* 196, 315-320.
- Ohta, T., Nagano, K., & Yoshida, M. (1986) *Proc. Natl. Acad. Sci. U.S.A.* 83, 2071-2075.
- Ovchinnikov, Y. A., Modyanov, N. N., Broude, N. E., Petrunkhin, K. E., Grishin, A. V., Arzamazova, N. M., Aldanova, N. A., Monastyrskaya, G. S., & Sverdlov, E. D. (1986) *FEBS Lett.* 201, 237-245.
- Periyasamy, S. M., Huang, W.-H., & Askari, A. (1983) *Comp. Biochem. Physiol. B* 76B, 449-454.
- Proudfoot, N. J., & Brownlee, G. G. (1976) *Nature (London)* 263, 211-214.
- Schmitt, C. A., & McDonough, A. A. (1986) *J. Biol. Chem.* 261, 10439-10444.
- Schwartz, A., Lindenmayer, G. E., & Allen, J. C. (1975) *Pharmacol. Rev.* 27, 3-134.
- Shull, G. E., Schwartz, A., & Lingrel, J. B. (1985) *Nature (London)* 316, 691-695.
- Shull, G. E., Lane, L. K., & Lingrel, J. B. (1986) *Nature (London)* 321, 429-431.
- Snider, L. D., King, D., & Lingrel, J. B. (1985) *J. Biol. Chem.* 260, 9884-9893.
- Stahl, W. L. (1986) *Neurochem. Int.* 8, 449-476.
- Sweadner, K. J. (1979) *J. Biol. Chem.* 254, 6060-6067.
- Thomas, R., Boutagy, J., & Gelbart, A. (1974) *J. Pharmacol. Exp. Ther.* 191, 219-231.
- Tobin, T., & Brody, T. M. (1972) *Biochem. Pharmacol.* 21, 1553-1560.
- Wallick, E. T., Pitts, B. J. R., Lane, L. K., & Schwartz, A. (1980) *Arch. Biochem. Biophys.* 202, 442-449.